Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Teva Appoints Itzhak Krinsky as Chairman for Japan, South Korea
September 18, 2012
- Chugai Provides All-Case PMS Data via iPad, Beginning with Avastin
September 18, 2012
- Kaketsuken Starts PIII Trial for Cell-Culture-Based New-Type Influenza Vaccine
September 18, 2012
- Astellas Launches Enzalutamide in the US
September 18, 2012
- 100,000 Registrations Expected by End of Year on Japan Vaccine’s Mobile Phone Vaccination Website
September 18, 2012
- Kyowa Kirin to Return Rights for Busulfex in Japan and Asia to Otsuka
September 18, 2012
- Detailing with iPad Rapidly Increases, Up 21.6 Points to 48.8%: Doctor Survey
September 14, 2012
- JT Sees Silver Lining in Pharmaceutical Biz 25 Yrs after Market Entry; 1st Approval Obtained for Proprietary Drug
September 14, 2012
- Eisai Ties up with US NPO to Support Vaccine Development for Tropical Diseases
September 14, 2012
- Eisai Launches Next Mainstay Product in Europe; Antiepileptic Perampanel
September 14, 2012
- MTPC Files for Additional Indication of Chronic Atrial Fibrillation for Maintate
September 14, 2012
- Bayer Yakuhin Granted Priority Review for NDA for Regorafenib
September 13, 2012
- Takeda Completes New Russian Factory, Full-Scale Operation Scheduled in 2014
September 13, 2012
- FDA Accepts Resubmission of NDA for Once-Monthly Aripiprazole Injection: Otsuka
September 13, 2012
- Pfizer Japan Files Add’l Indication of MS for Solu-Medrol Based on Data from Public Domain
September 13, 2012
- Eli Lilly Files Public Knowledge-Based Application for Gemzar for Malignant Lymphoma
September 12, 2012
- Wholesalers Unlikely to See Significant Progress in Price Negotiations By End of September
September 12, 2012
- Taisho Toyama, Eisai Launch Anti-Rheumatic Drug Kolbet/Careram on Sept. 12
September 12, 2012
- 6.3% Increase in Ethical Drug Sales in July: Crecon Report
September 11, 2012
- “Legal Compliance” Part of Employee Evaluations in Sales Division, Including Possible Cuts in Bonuses for Managers: MSD
September 11, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…